Drugdocs | Vizamyl

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Vizamyl

Chemical Name	flutemetamol F 18 injection
Dosage Form	Injection (intravenous; 150 MBq/mL (4.05 mCi/mL)
Drug Class	Radioactive diagnostic agents
System	Nervous
Company	GE Healthcare
Approval Year	2013

Indication

For Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline.

Last updated on 4/29/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Vizamyl (flutemetamol F 18 injection) Prescribing Information	2013	GE Healthcare, Medi-Physics, Inc., Arlington Heights, IL

Document Title	Year	Source
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).	2017	Cochrane Database of Systematic Reviews

Document Title	Year	Source
Canadian consensus guidelines on use of amyloid imaging in Canada: update and future directions from the specialized task force on amyloid imaging in Canada.	2016	The Canadian Journal of Neurological Sciences